Metherspan125 mcg

Metherspan is a semisynthetic ergot alkaloid uterotonic (oxytocic) agent with the following evidence-based indications:

Established / FDA-approved uses

• Prevention and treatment of postpartum hemorrhage due to uterine atony or subinvolution, used routinely after delivery of the placenta.
• Postpartum hemorrhage or excessive bleeding after abortion (post-abortion hemorrhage), used to promote firm uterine contraction and reduce blood loss.

Guideline-supported uses

• Recognized by WHO and obstetric guidelines as a second-line/alternative uterotonic for postpartum hemorrhage prevention and treatment when oxytocin is unavailable, ineffective, or contraindicated, or as an additional uterotonic in combination with oxytocin in refractory uterine atony.

Metherspan is intended strictly for use after delivery of the infant and placenta (postpartum or post-abortion); it must never be used to induce or augment labor, or at any time before delivery of the fetus.

Each tablet or ampoule for injection contains Methylergonovine Maleate as the active ingredient, typically available as 0.2 mg tablets and 0.2 mg/mL injectable ampoules. Methylergonovine Maleate is an established obstetric medicine used in hospital and clinical settings in Bangladesh and internationally as part of active management of the third stage of labor and postpartum hemorrhage care. Exact strengths, dosage forms, and inactive ingredients vary by manufacturer; refer to the specific product's package insert for full details.

Metherspan is a semisynthetic derivative of an ergot alkaloid (related to ergometrine/ergonovine) that acts as a potent, direct-acting uterotonic. It is administered by intramuscular, intravenous, or oral routes strictly in the postpartum or post-abortion period to produce sustained, firm contraction of the uterus, which compresses uterine blood vessels at the placental implantation site and reduces bleeding. It is a standard component of obstetric hemorrhage management, used only in clinical/hospital settings for this specific indication rather than as a routine outpatient medication.

Metherspan belongs to the ergot alkaloid class of drugs and is classified therapeutically as a uterotonic (oxytocic) agent used in obstetric hemorrhage management.

Methylergonovine Maleate acts directly on uterine smooth muscle, binding to serotonergic (5-HT2) and alpha-adrenergic receptors to produce sustained, tetanic uterine contractions, unlike the rhythmic contractions produced by oxytocin. This sustained contraction compresses the spiral arteries at the placental implantation site, substantially reducing postpartum blood loss. Methylergonovine Maleate also has vasoconstrictive activity on peripheral and coronary blood vessels, which underlies its cardiovascular adverse effects (notably hypertension and, rarely, vasospasm).

After oral administration, Methylergonovine Maleate is absorbed relatively rapidly, with uterine effects beginning within minutes; after intramuscular injection, onset occurs within 2-5 minutes, and after intravenous administration, effects begin almost immediately. It is metabolized in the liver (partly via CYP3A4) and excreted mainly in bile/feces with a smaller renal component. Its duration of uterotonic action is typically several hours per dose.

Metherspan tablets are taken orally, generally without regard to food, at evenly spaced intervals as directed by the physician. The injectable form is given only by a trained healthcare professional, by intramuscular injection as the preferred parenteral route; intravenous administration is reserved for emergencies and must be given slowly (over at least 60 seconds) with close blood pressure monitoring because of the risk of sudden hypertensive episodes and stroke. Metherspan is never self-administered by the patient.

Clinically significant interactions with Metherspan include:

• Potent CYP3A4 inhibitors (e.g., certain azole antifungals such as ketoconazole/itraconazole, macrolide antibiotics such as erythromycin/clarithromycin, and HIV protease inhibitors): co-administration can significantly increase ergot alkaloid blood levels, increasing the risk of vasospasm, peripheral ischemia, and ergotism; concurrent use should generally be avoided or requires close monitoring.
• Other vasoconstrictors or vasopressor agents (including other ergot alkaloids and certain sympathomimetics): additive vasoconstriction and hypertensive risk.
• Regional anesthetics/vasoconstrictor-containing local anesthetics: may potentiate hypertensive effects when used peripartum.

Always inform the treating physician of all other medications, including over-the-counter drugs, herbal products, and supplements, before Metherspan is administered.

Common side effects

• Hypertension (including sudden, severe elevations, especially with IV use)
• Nausea and vomiting
• Headache and dizziness
• Abdominal cramping/pain
• Palpitations

Less common but serious effects

• Severe hypertensive episodes, seizures, and stroke (rare, mainly associated with rapid IV administration)
• Coronary vasospasm or myocardial ischemia (rare)
• Peripheral vasospasm/ischemia, particularly with concurrent CYP3A4 inhibitor use (see Interactions)
• Tinnitus, chest pain, and dyspnea (uncommon)

Patients or caregivers should promptly report severe headache, chest pain, sudden high blood pressure, visual disturbances, or signs of poor circulation in the limbs to the treating physician.

Metherspan is contraindicated for use at any time before delivery of the fetus, as it produces sustained uterine contractions that can cause fetal distress, uterine rupture, and other serious complications; it is used only after delivery of the placenta, in the postpartum or post-abortion period. Use only if clearly needed for management of postpartum hemorrhage and only under close physician/hospital supervision, following the specific postpartum dosing guidance.

Metherspan is excreted into breast milk in small amounts and may, particularly with repeated dosing, reduce prolactin levels and interfere with lactation. Short courses used for standard postpartum indications are generally considered acceptable with breastfeeding, but the potential benefit should be weighed against the potential risk to the nursing infant, and a physician should be consulted regarding the lowest effective dose and duration.

Hypertensive and Cardiovascular Risk

Metherspan can cause sudden, severe hypertension, seizures, or stroke, particularly with rapid intravenous administration; the IV route should be reserved for emergencies and given only as a slow injection over at least 60 seconds with blood pressure monitoring. Use with particular caution in patients with any cardiovascular risk factors.

Vasospasm/Ergotism

Concurrent use with potent CYP3A4 inhibitors increases the risk of vasospasm and ergot toxicity affecting peripheral circulation (see Interactions); watch for signs such as numbness, tingling, or coldness of extremities.

Timing of Administration

Metherspan must be given only after delivery of the placenta; it is not used before delivery of the fetus (see Contraindications).

Hepatic/Renal Impairment

Use with caution in patients with hepatic or renal impairment, as reduced clearance may increase the risk of adverse effects.

Sepsis

Avoid use in patients with sepsis (see Contraindications).

Metherspan should be administered exactly as directed by the treating physician in a clinical setting; do not stop, extend, or repeat doses, or use this medicine outside of medical supervision.

Overdosage with Metherspan may present with severe hypertension, seizures, chest pain, peripheral vasospasm/ischemia (numbness, coldness, or discoloration of the extremities), nausea, vomiting, and, in severe cases, respiratory depression. If an overdose is known or suspected, seek immediate medical attention or contact emergency services / a poison control center right away. There is no specific antidote; management is supportive and may include blood pressure control and treatment of vasospasm under medical supervision. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), protected from light and excessive heat. Do not freeze. Keep out of reach of children. Use injectable ampoules promptly once opened and discard any unused portion.

Renal Impairment

Use with caution; reduced clearance may increase the risk of adverse effects. No well-established specific dose adjustment is defined; close monitoring is advised.

Hepatic Impairment

Use with caution, as Metherspan is hepatically metabolized; close monitoring is advised.

Elderly

Not typically applicable, as Metherspan is indicated specifically for postpartum/post-abortion patients.

Pediatric Use

See Pediatric Uses.

Cardiovascular Disease

Use with extreme caution, or avoid, in patients with hypertension, pre-eclampsia/eclampsia, or coronary/peripheral vascular disease (see Contraindications).

Metherspan is used for a short, defined period in the immediate postpartum or post-abortion setting: typically one or a few intramuscular or intravenous doses at the time of delivery/hemorrhage control, optionally followed by oral tablets given several times daily for up to about one week during the puerperium if ongoing uterine subinvolution or bleeding is present. It is not intended for long-term or chronic use, and treatment duration and continuation should always be determined by the treating physician.

Ergot alkaloid; uterotonic (oxytocic) agent.

Methylergonovine Maleate acts as a direct agonist at uterine smooth muscle serotonin (5-HT2) and alpha-adrenergic receptors, producing sustained, tetanic contraction of the uterus rather than the rhythmic contractions caused by oxytocin. This sustained contraction compresses the spiral arteries at the placental implantation site, reducing postpartum blood loss. Its action on vascular smooth muscle elsewhere in the body also produces generalized vasoconstriction, which accounts for its hypertensive and vasospastic adverse effects.

C

Metherspan is not a pediatric medication; it is indicated specifically for use in postpartum or post-abortion patients (i.e., women who have just delivered or had a pregnancy loss/termination), regardless of the mother's age, using the standard adult postpartum dosing described in Dosage and Administration. Safety and efficacy have not been established for any indication outside of this specific postpartum/post-abortion use, and Metherspan should not be used in children or adolescents for any other purpose.